Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928642 · ClinicalTrials.gov registry record · Phase 2
Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer
A Phase 2 study, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00928642 is a Phase 2 study that has completed, run by Henry M. Jackson Foundation for the Advancement of Military Medicine. The registered enrollment target is 8 participants.
The verdict
NCT00928642, a Phase 2 study, has completed, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and tolerability of the combination of Gleevec and Gemzar in patients with ovarian cancer, who have progressed after receiving at least one prior chemotherapy treatment. Gleevec is an oral chemotherapy drug used is this study and Gemzar is an IV chemotherapy drug used. Participation in the treatment portion of the study will continue as long as the patient's tumors shrink or remain stable and as long as the patient is able to tolerate the study drug. The follow-up portion of the study will last for 5 years.
Interventions
- DRUG imatinib mesylate by mouth
- DRUG Gemcitabine Intravenous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00928642
The ClinicalTrials.gov registry entry for NCT00928642 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which imatinib mesylate by mouth is the first listed.
NCT00928642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00928642 about?
NCT00928642 is a clinical study titled "Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer". This study will evaluate the efficacy and tolerability of the combination of Gleevec and Gemzar in patients with ovarian cancer, who have progressed after receiving at least one prior chemotherapy treatment. Gleevec is an oral chemotherapy drug used is this study and Gemzar is an IV chemotherapy dru...
What is the current status of trial NCT00928642?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2009-06. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00928642?
The interventions under investigation include: imatinib mesylate by mouth (DRUG), Gemcitabine Intravenous (DRUG).
Who is sponsoring clinical trial NCT00928642?
This trial is sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.